Multiple squamous cell carcinomas following introduction of nilotinib

Summary Background Nilotinib is a second generation tyrosine kinase inhibitor, used in the treatment of chronic myelogenous leukaemia (CML). Methods We assessed a 72‐year‐old woman who was treated with nilotinib for CML. Results During the year following commencement of nilotinib, the patient develo...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental dermatology Vol. 39; no. 7; pp. 791 - 794
Main Authors Peters, P., Rabbolini, D., Sinnya, S., Khosrotehrani, K., Wagner, G.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.10.2014
Oxford University Press
Subjects
Aged
Antineoplastic Agents - adverse effects
Carcinoma, Squamous Cell - chemically induced
Female
Humans
Leg
Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
Protein Kinase Inhibitors - adverse effects
Pyrimidines - adverse effects
Skin Neoplasms - chemically induced
Online AccessGet full text

Cover

More Information
Summary:Summary Background Nilotinib is a second generation tyrosine kinase inhibitor, used in the treatment of chronic myelogenous leukaemia (CML). Methods We assessed a 72‐year‐old woman who was treated with nilotinib for CML. Results During the year following commencement of nilotinib, the patient developed eight squamous cell carcinomas (SCCs) on her legs. Conclusions Development of SCC is a previously unreported adverse reaction to nilotinib.
Bibliography:istex:B9BEAAB8286F917A7062644ABADB698B8A88130C
ark:/67375/WNG-JWDSVJGW-G
ArticleID:CED12388
ISSN:0307-6938
1365-2230
DOI:10.1111/ced.12388